following an abbreviated submission:
dolutegravir (Tivicay®) is accepted for use within NHS Scotland.
Indication under review: in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected children aged >6 to 12 years of age.
SMC has previously accepted dolutegravir 50mg film-coated tablets for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age.
This SMC advice takes account of the benefits of a patient access scheme (PAS) that improves the cost-effectiveness of dolutegravir. This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice70KB (PDF)
Medicine details
- Medicine name:
- dolutegravir (Tivicay)
- SMC ID:
- 1253/17
- Indication:
- In combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected children aged >6 to 12 years of age.
- Pharmaceutical company
- ViiV Healthcare/GSK
- BNF chapter
- Infections
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 July 2017